The FDA’s Oncologic Drugs Advisory Committee voted against GSK’s application to reintroduce Blenrep, its antibody-drug conjugate for multiple myeloma, citing safety and clinical trial concerns. The committee highlighted high rates of ocular toxicities, including corneal ulcers, and issues with dose optimization. Low U.S. patient enrollment in pivotal trials further complicated the risk-benefit assessment. The negative panel votes dampen prospects of Blenrep’s comeback in the U.S. market.